MIRATI THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-12-13
- Employees
- 593
- Market Cap
- -
- Website
- http://www.mirati.com
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT06875310
- Locations
- 🇺🇸
Local Institution - 0347, Birmingham, Alabama, United States
🇺🇸Local Institution - 0581, Fullerton, California, United States
🇺🇸Local Institution - 0202, Long Beach, California, United States
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06801418
- Locations
- 🇺🇸
ICON - Lenexa, Lenexa, Kansas, United States
🇺🇸ICON Development Solutions, San Antonio, Texas, United States
🇺🇸ICON - Salt Lake City, Salt Lake City, Utah, United States
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05924152
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Daytona Beach (Labcorp Clinical Research Unit Daytona Beach), Daytona Beach, Florida, United States
A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
- Conditions
- Healthy Adults
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05868356
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc, Dallas, Texas, United States
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
- Conditions
- Advanced CancerMetastatic CancerMalignant Neoplasm of Lung
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05853575
- Locations
- 🇺🇸
Providence Medical Foundation - Research, Santa Rosa, California, United States
🇺🇸Local Institution - 104, Chicago, Illinois, United States
🇺🇸Local Institution - 103, Minneapolis, Minnesota, United States
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
- Conditions
- Solid Tumor, AdultNSCLCAdvanced CancerMetastatic CancerMalignant Neoplastic Disease
- Interventions
- Drug: nab-Sirolimus
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05840510
- Locations
- 🇺🇸
Local Institution - 019-104, Cleveland, Ohio, United States
🇺🇸Local Institution - 019-101, Nashville, Tennessee, United States
🇺🇸Local Institution - 019-102, Houston, Texas, United States
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Conditions
- Advanced Solid TumorColo-rectal CancerNon-small Cell Lung CancerSolid TumorPancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05737706
- Locations
- 🇺🇸
Local Institution - 311, Phoenix, Arizona, United States
🇺🇸Local Institution - 309, New Haven, Connecticut, United States
🇺🇸Local Institution - 301, Lady Lake, Florida, United States
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
- Conditions
- Advanced NSCLCMetastatic Lung Cancer
- Interventions
- Combination Product: PembrolizumabCombination Product: Cisplatin/Carboplatin
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05609578
- Locations
- 🇺🇸
Local Institution - Unk025, Anchorage, Alaska, United States
🇺🇸Local Institution - 017-591, Glendale, Arizona, United States
🇺🇸Local Institution - 017-821, Phoenix, Arizona, United States
A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
- Conditions
- Non Small Cell Lung CancerAdvanced Solid TumorSolid TumorColo-rectal Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT05578092
- Locations
- 🇺🇸
University of Texas Health Science Center at Tyler, Tyler, Texas, United States
🇺🇸Local Institution - 001-120, Colorado Springs, Colorado, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05255276
- Locations
- 🇺🇸
Labcorp Drug Development Clinical Research Unit, Dallas, Texas, United States